Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease

Recruiting now · Not applicable

Conditions studied: Pyrophosphate, Fetuin A, IL1, IL6, TNFalpha, Control

In brief

The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.

Key facts

Study ID

NCT06300788

Run by

Centre Hospitalier Universitaire de Nice

People needed

60

Starts

2024-05-27

Expected to finish

2027-11-27

Last updated by the study team

2026-07-27

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All groups :
• Minor patients (<18 years)
• Patients of both sexes
• Informed patients and parents who have signed the informed consent form
• Patients affiliated to social security
• Control group :
• Patients with no particular pathology undergoing surgery and receiving a preoperative check-up
• CKD groups :
• Patients on dialysis for more than 3 months, regardless of technique
• Kidney transplant patients
• Patients with CKD, whatever the cause

You may not qualify if…

• Progressive cancer or kidney disease
• Treatments that may modify PPi concentration (e.g. bisphosphonates)

Where it is running

• CHU Nice - Hôpital de l'Archet 2 — Nice, Alpes-Maritimes, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.